Tarlatamab Side Effects
Applies to tarlatamab: intravenous powder for injection.
Warning
Tell your medical caregivers if you have symptoms of a serious side effect, such as fever, chills, trouble breathing, vomiting, or severe tiredness.
Tarlatamab can also cause life-threatening nerve problems. Tell your caregivers or seek emergency medical attention if you have problems with speech, problems with thinking or memory, confusion, or a seizure.
Tarlatamab can increase your risk of serious bleeding. Stop using this medicine and call your doctor at once if you have severe stomach pain, bloody or tarry stools, coughing up blood, or any heavy or unusual bleeding.
Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
-
low blood cell counts--fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath;
-
signs of infection--fever, chills, sore throat, body aches, unusual tiredness, loss of appetite, bruising or bleeding; or
-
symptoms of liver failure--diarrhea, loss of appetite, pain or swelling in your stomach, swelling in your legs, easy bleeding, drowsiness, confusion, or jaundice (yellowing of the skin or eyes).
Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.
Common side effects may include:
-
abnormal lab results;
-
metallic taste in your mouth;
-
muscle or bone pain;
-
tiredness;
-
fever; or
-
loss of appetite.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For Healthcare Professionals
Applies to tarlatamab: intravenous powder for injection.
Hematologic
Very common (10% or more): Anemia (27%), decreased lymphocytes all grades (84%), decreased hemoglobin (58%), decreased white blood cells (44%), decreased platelets (33%), decreased neutrophils (12%)[Ref]
Immunologic
Very common (10% or more): Cytokine release syndrome (55%)[Ref]
Musculoskeletal
Very common (10% or more): Musculoskeletal pain (30%)[Ref]
Metabolic
Very common (10% or more): Hyponatremia (68%), decreased potassium (50%), decreased magnesium (33%), increased sodium (26%)[Ref]
Genitourinary
Very common (10% or more): Urinary tract infection (10%)[Ref]
Hepatic
Very common (10% or more): Increased hepatic enzymes: AST (44%), ALT (42%)
Respiratory
Very common (10% or more): Dyspnea (17%), cough (17%)
Common (1% to 10%): Pneumonia
Other
Very common (10% or more): Fatigue (51%), pyrexia (36%), decrease appetite (34%)[Ref]
General
The most common adverse events were cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite and musculoskeletal pain.[Ref]
Nervous system
Very common (10% or more): Dysgeusia (36%)[Ref]
Renal
Very common (10% or more): Increased creatinine (29%)
Gastrointestinal
Very common (10% or more): Nausea (22%), constipation (30%)[Ref]
More about tarlatamab
- Check interactions
- Compare alternatives
- Dosage information
- During pregnancy
- Drug class: bispecific T-cell engagers (BiTE)
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
References
1. (2024) "Product Information. Imdelltra (tarlatamab)." Amgen USA
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.